11基因表达谱评分在AJCC v8 II期皮肤黑色素瘤FFPE组织中的临床验证
本研究纳入2000至2016年诊断的II期皮肤黑色素瘤患者,对245例前瞻性收集的FFPE组织检测11基因表达谱评分(GEPS),以GEPS≤0 vs >0二分类评估其对黑色素瘤特异性生存(MSS)、无远处转移生存(DMFS)和无复发生存(RFS)的预后价值。中位随访41个月,高GEPS组(n=154)与低GEPS组(n=91)的MSS(p=0.018)、DMFS(p=0.005)和RFS(p=0.009)差异均有统计学意义。多变量Cox回归显示GEPS对MSS具有独立预后意义(HR=1.55;p=0.006)。
要点
- GEPS在II期皮肤黑色素瘤中为MSS的独立预后因素(HR=1.55;p=0.006)。
- 高GEPS组5年与10年MSS分别为82%和67%,低GEPS组10年MSS为92%。
- GEPS高与低组间DMFS(p=0.005)和RFS(p=0.009)差异显著。
核心结论
- GEPS被验证为II期皮肤黑色素瘤MSS的独立预后因素。
- 当II期皮肤黑色素瘤可获得全身治疗时,GEPS可用于治疗决策。
研究设计与样本
- 纳入2000至2016年诊断的II期皮肤黑色素瘤患者,要求原发肿瘤组织可用。
- 共245例患者可测定GEPS,其中女性111例、男性134例,中位随访41个月。
- GEPS以二分类参数(≤0 vs >0)评估,终点为MSS、DMFS和RFS。
主要发现
- GEPS测定值范围为-0.7至3.53。
- 高GEPS组(n=154)与低GEPS组(n=91)的MSS差异有统计学意义(p=0.018)。
- 高GEPS组与低GEPS组的DMFS差异有统计学意义(p=0.005)。
- 高GEPS组与低GEPS组的RFS差异有统计学意义(p=0.009)。
- 低GEPS组5年和10年MSS均为92%,高GEPS组5年和10年MSS分别为82%和67%。
关键数值与推荐
- 多变量Cox回归显示GEPS对MSS具有独立显著性(HR=1.55;p=0.006)。
- 多变量Cox回归显示肿瘤厚度对MSS具有独立显著性(HR=1.21;p<0.001)。
- 多变量Cox回归显示年龄对MSS具有独立显著性(HR=1.05;p=0.002)。
临床怎么用
- 对II期皮肤黑色素瘤患者可检测原发肿瘤FFPE组织的GEPS以进行风险分层。
- GEPS高提示MSS、DMFS和RFS较差,可辅助识别高风险II期患者。
- 在II期皮肤黑色素瘤全身治疗可及的情况下,GEPS可结合临床用于治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant therapies have been approved for patients with AJCC (American Joint Committee on Cancer) stage III and stage IV cutaneous melanoma (CM) after complete resection. These therapies might also be indicated for patients with high-risk stage II CM. MATERIAL AND METHODS: We included patients diagnosed with stage II melanoma between 2000 and 2016 and for which primary tumour tissue was available. The prognostic value of the 11-gene expression profiling score (GEPS) was evaluated as a dichotomized parameter (GEPS ≤0 vs. >0). Endpoints of the analysis were melanoma specific survival (MSS), distant metastasis-free survival (DMFS) and relapse-free survival (RFS). RESULTS: GEPS was determined in 245 patients ranging between -0.7 and 3.53. A total of 111 females and 134 males were included; the median follow-up was 41 months. Kaplan Meier analyses showed statistically significant survival differences between patients with high GEPS (n = 154) and low GEPS (n = 91) for MSS (p = 0.018), DMFS (p = 0.005) and RFS (p = 0.009). The 5-year and 10-year MSS was 92% in the low-GEPS and 82% and 67% in the high-GEPS group, respectively. Multivariate Cox regression analysis showed independent significance for MSS of GEPS (HR = 1.55; p = 0.006), tumor thickness (HR = 1.21; p < 0.001) and age (HR1.05; p = 0.002). CONCLUSION: GEPS was validated as independent prognostic factor for MSS in stage II CM and could be used for therapeutic decisions when systemic therapies become available in stage II CM.
引用
- Amaral TMS, Hoffmann MC, Sinnberg T, et al. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. Eur J Cancer. 2019. PMID: 31838403. doi:10.1016/j.ejca.2019.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。